Back

Placebo Response Rates in Randomized Controlled Trials (RCTs). A meta-analysis

Principal Investigators: C. Sadaghiani, PhD

Affiliations: University Hospital Freiburg, Department of Environmental Medicine and Hospital Epidemiology, Germany

Background: Since Beecher (1955) pointed to the importance of the placebo as a potentially powerful therapeutic intervention, the debate has not ceased. The scientific community is divided into two groups concerning the therapeutic relevance of placebo or unspecific effects: those who believe that placebos can influence physical health and those who don’t. Part of the discussion is possibly based on confusion in defining and measuring placebo effects. However, the question still remains whether the success in placebo groups is solely due to artifacts (e.g., regression to the mean, time course of the illness, measuring artifacts), or if there really do occur clinically relevant changes?

Method: We searched the medical literature from 1992 to 1997 (Medline, Cochrane Library, 1997) for long-term RCTs (double-blind, placebo-controlled, duration > 12 weeks). Search terms were 'placebo', 'double-blind', 'RCT', 'meta-analysis', 'long', 'studies', and 'treatment outcome'. These search terms were combined with different strategies. 141 studies fulfilled our inclusion criteria. Formal characteristics were coded: disease treated (ICD-10), duration of study, improvement with placebo and with medical treatment (% patients improved), attrition rate, and evaluation according to intent-to-treat. Two independent raters coded study quality.

Hypotheses: We assumed if a large part of the placebo response rates in RCTs are due to artifacts (e.g., study quality), we should find some indication for this in correlations between study characteristics representing these variables and the amount of placebo response rates.

Results: We found a highly significant correlation between placebo and treatment response rate across diseases (r=.78; p<.001). Also, there were significant relationships between placebo response rates and duration of study (r=.41), prevention trials (r=.59) and trials of ischemic heart disease (r=.45). Placebo response rates were lower in trials of psychotropic substances, dementia and anti-epileptic trials. Surprisingly, study quality and other characteristics of the studies were unrelated. In a regression analysis, the treatment response rate was the only substantial predictor (ß=.75) and explained approx. 60% of the variance. These results are a strong argument against the artifact hypothesis of placebo effects. Natural history also is an unlikely explanation for this phenomenon, which warrants further scrutiny.



 





Funded Research